Compare Quest Diagnostics Inc (DGX) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Workiva Inc — how do they compare? Quest Diagnostics Inc trades at $230.74 (market cap $25.48B), while Workiva Inc trades at $73.69 (market cap $4.01B). The key difference: Quest Diagnostics Inc is far larger — about 6.4× Workiva Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Workiva Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Workiva Inc for 21 Days on average.
| DGX | WK | |
|---|---|---|
Market Cap | $25.48B | $4.01B |
Volume | 941,866 | 1,301,708 |
Sector | Health | Technology |
52-Week High | $247.45 | $93.31 |
52-Week Low | $173.49 | $44.31 |
Typical Hold Time | 56 Days | 21 Days |
Enterprise Value | $31.23B | $3.99B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
WK trades at $73.79, up 3.16% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $0.798. Revenue grew to $966 million in 2026, turning a net loss in 2025 into a $47 million profit. Analyst sentiment is overwhelmingly positive, with 16 buy ratings and a consensus price target of $86.
The outlook for WK is favorable, driven by consistent earnings outperformance and revenue growth, though high valuation multiples like a P/E of 87.73 pose risks. Key opportunities include AI-driven product innovations and inclusion in investment analyses, while risks involve competitive pressures and reliance on continued execution. The stock's proximity to its 52-week high suggests momentum but warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
